June 24, 2021
2 min watch
Save
VIDEO: ASCO presentation addresses area of unmet need in EGFR-positive NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Nathan A. Pennell, MD, PhD, spoke with Healio about a presentation focused on patients with EGFR-positive non-small cell lung cancer who have relapsed with osimertinib.
According to Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, the “most interesting” preliminary data from this presentation was analyses of biomarker response.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview; Baumi J, et al. Abstract 9006. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Disclosures:
Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.